A novel nonsense mutation c.424G>T (p. G142X) in the first exon of XLas leading to osteopetrosis

Short title: XLas mutation and osteopetrosis

Xiang Chen¹, Ph. D, Yang Meng¹, Ph. D, Ying Xie¹, B.S, Shan Wan¹, M. S., Li Li²,
B.S, Jie Zhang³, B.S, Bo Su³, M.S, Xijie Yu^{1*}, Ph. D

¹Laboratory of Endocrinology and Metabolism, Department of Endocrinology, State
Key Laboratory of Biotherapy, West China Hospital, Sichuan University, Chengdu,
610041, China

²Laboratory of Pathology, West China Hospital, Sichuan University, Chengdu, 610041,
China

³Core Facility of West China Hospital, Sichuan University, Chengdu, 610041, China

Corresponding author:

Xijie Yu, M.D. & Ph.D.

Laboratory of Endocrinology and Metabolism, Department of Endocrinology, State
Key Laboratory of Biotherapy, West China Hospital, Sichuan University,
No. 37 Guoxue Xiang, Chengdu, China

Tel: +86-28-8542-2362,

Fax: +86-28-8542-3459,

Email: xijieyu@scu.edu.cn or xijieyu@hotmail.com

Abstract

GNAS is one of the most complex gene loci in the human genome and encodes multiple gene products. XLas, the extra-large isoform of alpha-subunit of the stimulatory guanine nucleotide-binding protein (Gas), is paternally inherited. Although XLas can mimic the action of Gas, its significance remains largely unknown in humans. Here we report a patient presented with increased bone mass, hypophosphatemia, and elevated parathyroid hormone levels. His serum calcium was in the lower limit of normal range. DEXA scan revealed progressive increase in the bone density of this patient. Whole exome sequencing of this subject found a novel nonsense mutation c.424G>T (p. G142X) in the first exon of XLas, which was inherited from his father and transmitted to his daughter. This mutation was predicted to exclusively influence the expression of XLas, while may have no significant effects on other gene products of this locus. SaOS2 cells transfected with mutant XLas failed to generate cAMP under parathyroid hormone stimulation, indicating skeletal resistance to this hormone. This subject showed higher circulating SOST, DKK1 and OPG levels, while lower RANKL levels and RANKL/OPG ratio, leading to reduced bone resorption. It is speculated that this patient may belong to a very rare type of pseudohypoparathyroidism with selective skeletal resistance but normal renal tubular response to parathyroid hormone. Our findings indicate that XLas plays a critical role in bone metabolism and GNAS locus should be considered as a candidate gene for high bone mass.

Author summary

GNAS has been regarded as one of the most complex gene loci and encodes multiple transcripts, including Gs α , XLas, NESP55 and A/B transcripts. These isoforms share the same 2-13 exons with alternative first exons. Previously reported mutations often disrupt multiple protein-coding transcripts in addition to that encoding Gs α , making it difficult to distinguish the contributions of each transcript to disease phenotypes. Here we first report a novel nonsense mutation c.424G>T (p. G142X) in the first exon of XLas in a subject presenting with high bone mass, unclosed cranial suture, and persistent hypophosphatemia, and elevated parathyroid hormone (PTH) levels. This is the first report of a mutation located in the first exon of XLas in humans, which was predicted to exclusively influence the expression of XLas, while may have no significant effects on other gene products of this locus. SaOS2 cells transfected with mutant XLas failed to generate cAMP under PTH stimulation, indicating skeletal resistance to this hormone. Our study suggests that XLas has an important physiological role in humans, and is involved in skeletal PTH/cAMP pathway. Our findings also indicate GNAS locus should be considered as a candidate gene for high bone mass.

key words: osteopetrosis; hypophosphatemia; XLas; parathyroid hormone; pseudohypoparathyroidism

Funding

The National Natural Science Foundation of China.

Declaration of Interests

66 The authors declare no competing interests.

67

68

Introduction

GNAS has been regarded as one of the most complex gene loci in the human genome and undergoes tissue-specific imprinting [1]. Epigenetic event contributes to tissue specific imprinting of $Gs\alpha$, which leads to phenotypic variability in GNAS mutations. Heterozygous, maternally inherited inactivating mutations in one of the 13 GNAS exons encoding $Gs\alpha$ lead to pseudohypoparathyroidism type 1a (PHP1a). However, paternal inheritance of the same mutations causes pseudopseudohypoparathyroidism (PPHP), which manifests as Albright's hereditary osteodystrophy (AHO) without hormonal resistance [2].

The GNAS complex locus encodes multiple transcripts, including $Gs\alpha$, XL α s, NESP55 and A/B transcripts [3]. These isoforms share the common exons 2–13 with four alternative promoters and first exons [4]. $Gs\alpha$ (NM_000516.5) couples seven transmembrane receptors to adenylyl cyclase and is involved in intracellular cAMP generation [5]. In most tissues, $Gs\alpha$ is biallelically expressed. However, only maternal allele of $Gs\alpha$ is expressed in renal proximal tubules. XL α s (NM_080425.3), the extra-large $Gs\alpha$ isoform, is paternally expressed [6]. XL α s shows a more restricted tissue distribution than $Gs\alpha$, and is primarily expressed in neuroendocrine tissues. Although XL α s can mimic the actions of $Gs\alpha$ to stimulate adenylyl cyclase to generate cAMP, obviously different cellular actions have been found between XL α s and $Gs\alpha$, possibly due to their different activation-induced trafficking [6-8]. Presently it is unclear whether XL α s has an important physiological function in humans. Here we first report a subject with high bone mass (HBM) carrying a novel mutation in the first exon of XL α s, which

indicates that XLas may play a role in bone metabolism.

Materials and Methods

Subjects

This study was approved by the Institutional Review Boards of West China Hospital, Sichuan University. All subjects were given written, informed consent before participating in the study. The proband was a 44-year-old man, first seen at the outpatient unit of West China Hospital in May 2014, with complaints of back pain for 12 years, aggravated with double hip pain for 2 years. The patient's height was 170 cm, and body weight was 62kg. Laboratory evaluation revealed elevated PTH, low serum phosphorous and 25-hydroxyvitamin D levels. His serum calcium was at the lower limit of the normal range. Serum levels of bone specific alkaline phosphatase (BALP), N-mid osteocalcin (OCN) and type 1 collagen cross-linked C-telopeptide (CTX) were increased. He had normal thyroid stimulating hormone (TSH) and free T4 (FT4) levels. His mean bone mineral density, T and Z scores of lumbar vertebrae, L1–L4, were 1.936 (gm/cm²), 7.1 and 7.6, respectively. His mean bone mineral density, T and Z scores of femoral neck were 1.406 (gm/cm²), 3.3 and 3.8, respectively (table 1). This patient had no history of fluorosis and hepatitis C infection.

Circulating SOST, DKK1, receptor activator of RANKL and OPG levels

Plasma levels of SOST, RANKL and OPG were detected using kits from abcam (Cambridge, UK). Serum DKK1 levels were also measured using ELISA methods (R&D Systems, Inc., Minneapolis, USA). Twenty gender- and age- matched healthy adult males were selected as controls.

Mutation analysis

WES of the proband was performed and the detected possible mutations were further analyzed in DNA samples from his parents, brother and children (KingMed Diagnostics, Guangzhou, China).

Osteoclast culture

Osteoclasts from human peripheral blood were cultured as previously described ¹⁰. PBMCs were isolated using Ficoll-Hypaque Solution. Cells were washed in PBS twice, and plated on 24-well plates at a density of 1×10⁶/well at 37°C in α-MEM, supplemented with 10% FBS, 1% penicillin/streptomycin and 25 ng/ml of macrophage colony stimulating factor (M-CSF) (R&D Systems, Inc., Minneapolis, USA). 6 days later, OC differentiation was induced with the medium supplemented with both 25ng/ml of M-CSF and 30ng/ml RANKL (R&D Systems, Inc., Minneapolis, USA). 7 days later, TRAP staining was performed using a kit from Sigma-Aldrich (sigma Chemical Co., St. Louis, MO, USA). TRAP-positive cells containing 3 or more nuclei were counted as OCs. 6mm*6mm bovine cortical bone slices were put into cell culture wells at the beginning of OC differentiation. 7 days after co-cultures, the slices were removed and evaluated for OC morphology and pit formation by scanning electron microscope (INCA PENTAFET X3, Oxford Instruments, Abingdon, Oxfordshire, UK).

Plasmids

WT XLas cDNA was synthesized according to the sequence from Genbank database, and the mutant XLas cDNA was generated by site-directed mutant PCR and was confirmed by sequencing. The WT and mutant XLas cDNAs, tagged with enhanced

green fluorescent protein (EGFP), were cloned into expression vector GV144 (Shanghai Genechem Co., Ltd., Shanghai, China).

Expression and location of WT and Mutant XLas in SaOS2 cells

Human SaOS2 cells were maintained in α MEM containing 10 % FBS, 10 mM HEPES, 0.2 M L-Glutamine and penicillin/gentamycin at 37 °C with 5 % CO₂. After reaching 70–80% confluence, cells were transfected with 1.5ug DNA per well with 1:3 ratio of Xtreme^{HP} transfection reagent (Roche Diagnostics Ltd., Indianapolis, USA). 72h after transfection, cells were fixed in 4% PBS-buffered paraformaldehyde at room temperature for 5min. Cell nuclei were dyed with DAPI.

72h after transfection, the growth medium was aspirated and the total RNA was extracted using a Trizol reagent (Thermo Fisher Scientific Inc., Waltham, USA). Relative gene expression levels were normalized to GAPDH, and analyzed with 2^{- $\Delta\Delta$ Ct} method.

cAMP production stimulated by PTH

72h after transfection, the confluent monolayer SaOS2 cells were serum starved for 6 hours prior to treatment. Cells were first treated with 3-isobutyl-1-methylxanthine (IBMX, 1mM) (R&D Systems, Inc., Minneapolis, USA) for 15min and then treated with PTH(1-34) (50 nM) (R&D Systems, Inc., Minneapolis, USA) for 20 min. Cells were lysed using 0.1M HCL and cAMP levels were measured using a direct cAMP ELISA kit (Sigma Chemical Co., St. Louis, MO, USA).

Results

Clinical and laboratory findings

The proband was prescribed caltrate plus vitamin D₃ to exclude the secondary hyperparathyroidism induced by vitamin D deficiency. The serum levels of 25-hydroxyvitamin D₃ were reversed within the normal range, however, elevated PTH and hypophosphatemia persisted and his serum calcium levels remained at the lower limit of the normal range. It could be seen from table 1 that the levels of B-ALP, OCN and CTX showed a tendency to decrease during the past 4 years. He had low TRP (%) (percent tubular reabsorption of phosphate) and TmPO₄/GFR (tubular maximum phosphate reabsorption per glomerular filtration rate) (table 1), indicating reduced tubular reabsorption of phosphorus. Compared with the other members of his family, the proband showed lower Fractional Excretion of Calcium (FECa) (table 1), indicating low urinary calcium excretion. The DXA scan performed in February 2017 and October 2018 revealed progression in the bone density of the proband (table 1). X-ray of skull showed unclosed coronal suture and sagittal suture. Diffuse increase in bone mass was seen in the vertebral body. Pelvic X-ray showed bilateral femoral neck fractures and uneven bone density in pelvic. Cortical bone thickening was seen in long bones (Fig.1A-D). His father had a history of fracture and was unable to walk for 5 years for unknown reasons. The proband or his family members did not show heterotopic ossifications in their skeletons.

Compared with the normal controls, this subject showed significantly higher SOST, OPG, and DKK1 levels, while lower RANKL levels and decreased RANKL/OPG ratio (table 1). His father also had higher SOST and OPG levels, as well as lower RANKL

179 levels and decreased RANKL/OPG ratio (table 1).

180

181 **Table 1. Clinical and Biochemical Results**

	Proband				Father	Mother	Daughter	Son	Brother	Reference Range
	2014-3-6 ^{&}	2017-2-20	2018-10-31*	2018-11-19						
Age (y)	44	47	48	48	84	70	12	10	45	N/A
Bone fractures	Yes	Yes	Yes	Yes	Yes	No	No	No	No	N/A
BMD (L1–L4)(gm/cm²)	1.936	2.217	2.368	N/A	N/A	N/A	N/A	N/A	0.979	N/A
T /Z values of L1-L4	7.1/7.6	9.5/9.9	10.7/11.3	N/A	N/A	N/A	N/A	N/A	-0.9/-0.5	N/A
BMD (femoral neck)(gm/cm²)	1.406	1.594	1.637	N/A	N/A	N/A	N/A	N/A	0.769	N/A
T /Z values of femoral neck	3.3/3.8	4.7/5.3	5.1/5.7	N/A	N/A	N/A	N/A	N/A	-1.6/-1.2	N/A
Blood tests										
Phosphate(mmol/L)	0.72	0.53	0.40	0.65	1.11	1.12	1.41	1.53	0.82	adults:0.81-

										1.45; 0-12y:1.29- 2.26
Calcium (mmol/L)	2.19	2.15	2.18	2.25	2.07	2.25	2.24	2.41	2.34	adults:2.1- 2.7; 2-12y: 2.2- 2.7
Magnesium(mmol/L)	0.78	0.85	0.90	0.80	0.87	0.97	0.89	0.83	0.98	0.67-1.04
B-ALP(ug/L)	>132	>116	95.54	100.29	25.30	55.34	38.33	>124	45.84	11.4-24.6
OCN	152.7	N/A	51.8	N/A	N/A	N/A	N/A	N/A	N/A	24-70
PTH (pmol/L)	9.91	12.77	8.23	10.34	7.65	8.45	13.3	5.16	6.08	1.6-6.9
25(OH)D₃(ng/mL)	30.68	65.69	78.41	76.84	29.85	41.07	32.47	38.04	41.20	47.7-144
CTX(ng/mL)	2.67	0.942	0.825	0.632	0.60	1.13	0.903	1.52	0.269	0.30-0.584

TSH (mU/L)	2.53	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	0.27-4.2
FT4 (pmol/L)	15.34	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	12.0-22.0
Plasma SOST (pg/mL)	N/A	2740	N/A	N/A	1854	667	672	767	706	714±199
Plasma OPG (pg/mL)	N/A	652	N/A	N/A	1200	695	421	379	387	377±102
Plasma RANKL(pg/mL)	N/A	102	N/A	N/A	129	119	155	142	127	152±94
RANKL/OPG ratio	N/A	0.15	N/A	N/A	0.11	0.17	0.37	0.38	0.33	0.31±0.11
Serum DKK1 (pg/mL)	N/A	5388	N/A	N/A	3193	3617	3995	3086	1341	3180±869
Urine tests										
Phosphate (mmol /24 h)	11.03	11.19	N/A	N/A	N/A	N/A	N/A	N/A	N/A	22-48
Calcium (mmol /24 h)	0.39	0.42	N/A	N/A	N/A	N/A	N/A	N/A	N/A	2.5-7.5
Magnesium (mmol /24 h)	2.58	2.93	N/A	N/A	N/A	N/A	N/A	N/A	N/A	3.0-5.0

h)										
TRP (%)	N/A	73	76	87	82	88	95	97	95	80-95
TmPO4/GFR(mg/dL)	N/A	1.34	1.19	1.37	2.22	3.06	4.19	4.64	2.41	2.2-4.2
FECa (%)	N/A	0.71	1.01	N/A	9.45	27.98	2.28	2.04	16.88	N/A

182 Note: & caltrate plus vitamin D₃ were prescribed; * Phosphorus supplement was prescribed.

Mutational Analysis

Whole exome sequencing (WES) of the proband was performed. A novel heterozygous missense mutation c.424G>T (p. G142X) was found in exon 1 of GNAS isoform XLas (NM_080425.3). This changed the codon (GGA) for 142nd amino acid glycine (G) to a stop codon (UGA) (Fig.2A) and was predicted to be deleterious, leading to early termination of protein translation. This mutation was not found in OMIM, HGMD and Clinvar database, and was also not included in population databases, including 1000 Genomes, dbSNP, Exome Variant Server and ExAC Browser. This mutation was also found in his father and daughter. His mother, brother and son were negative.

XLas, a long Gs α variant, uses an alternative first exon, which splices into exons 2–13 of Gs α . Alex (NM_001309883.1) is also generated from an alternative reading frame of the XLas transcript[9], which has no similarity to other proteins encoded by this gene. This mutation locates in the first exon of XLas, which is also located in the coding region of Alex and generates a synonymous mutation c.237G>T (p. P79P) (Fig.2B). Gs α , NESP55 and A/B transcripts were predicted to be unaffected.

Osteoclast(OC) formation and function

Osteoclasts were induced from human peripheral blood mononuclear cells (PBMCs) to observe the ability of in vitro osteoclast formation and bone resorption. TRAP staining reveal decreased osteoclast numbers induced from the PBMCs of the patient (Fig.3G). However, scanning electron microscopy observation of the co-cultured bone slices showed normal osteoclast morphology and pit formation of the osteoclasts from the patient (Fig. 3C-F).

Expression and location of Wild type (WT) and mutant XLas in SaOS2 cells

WT and mutant XLas cDNA were transfected into human SaOS2 cells. In these transfected cells, EGFP-tagged WT XLas was localized to the cell membrane and

cytoplasm. On the contrary, the expression of EGFP-tagged mutant XLas was absent in transfected SaOS2 cells (Fig. 4). The mRNA expression of WT and mutant XLas was significantly higher in transfected cells than in cells transfected with empty vector (Fig.3H).

cAMP production

The ability of cAMP generation under PTH stimulation in transfected cells were determined. SaOS2 cells transfected with WT XLas showed higher cAMP production after PTH stimulation, while SaOS2 cells transfected with mutant XLas showed similar lower cAMP production as that in SaOS2 cells transfected with empty vector (Fig.3I).

Discussion

This is the first report of a mutation located in the first exon of XLas in humans, which was predicted to have no significant effects on other gene products of this locus. This novel mutation causes a new constellation of clinical features including high bone mass, unclosed cranial suture, fractures, hypophosphatemia, and elevated PTH levels. By contrary, the major clinical features of AHO, caused by heterozygous inactivating mutations in Gs α -coding GNAS exons, include obesity with round face, short stature, brachydactyly, subcutaneous ossification, and mental retardation [4]. In some cases, TSH, gonadotropins and GHRH resistance may be variably present [10]. Previously reported mutations often disrupt multiple protein-coding transcripts in addition to that encoding Gs α [11, 12], making it difficult to distinguish the contributions of each transcript to disease phenotypes. Therefore, this case is very rare and precious. Our study indicates XLas plays a key regulatory role in bone metabolism and may be involved in PTH/cAMP signaling pathway in physiological conditions.

Gs α is able to stimulate the production of the second messenger cAMP under PTH stimulation. However, the significance of XLas still remains largely unknown in

humans with conflicting results [6, 8, 13]. The abnormal skeletal phenotype in this patient implies that XLas has an important physiological role in humans. Our *in vitro* study clearly demonstrated that WT XLas was capable of stimulating cAMP production in human SaOS2 cells, which was blunted by G142X mutation. PTH shows both anabolic and catabolic actions on the skeleton, depending on the ways in which PTH is administrated [14]. Through targeting cAMP/PKA pathways, PTH favors bone resorption by stimulating RANKL while inhibiting OPG expression in osteoblasts/osteocytes via the PTH1R, rendering increased RANKL/OPG ratio [15-17]. Also through cAMP/PKA signaling pathway, PTH induces bone formation, at least in part, by its ability to downregulate SOST and DKK1 expression in osteocytes [14, 18-21]. This proband showed increased circulating levels of SOST, DKK1 and OPG, while decreased RANKL levels and reduced RANKL/OPG ratio, concurrently with the elevated PTH levels, indicating impaired skeletal response, at least partly, to PTH as a result of lower cAMP production induced by G142X mutation (Figure 5). Our study suggested that XLas may exert similar regulatory effects as Gsα regarding the expression of target genes as well as cAMP production. There is another possibility that the observed phenotype may be primarily resulted from XLas deficiency in bone but not from the action of PTH. However, based on our *in vivo* and *in vitro* studies, especially the changes of circulating SOST, DKK1, RANKL and OPG levels, it is more likely to be secondary to the impaired PTH/cAMP pathway in the skeletal tissue.

Although SOST, DKK1, RANKL and OPG have not been established as the clinical bone markers in humans, previous studies have suggested that disorders of parathyroid influence the circulating levels of these factors. Serum SOST levels are decreased in primary hyperparathyroidism and increased in hypoparathyroidism [22, 23], while serum DKK1 levels are increased in hyperparathyroidism [24]. Elevated RANKL/OPG

ratio has also been found in subjects with hyperparathyroidism [25, 26]. However, no related studies have been reported in subjects with PHP. Except for serum DKK1 levels, the elevated plasma SOST levels and reduced RANKL/OPG ratio may indicate decreased parathyroid function in proband and his father.

This patient showed a progressive increase in BMD, and the underlying mechanism was speculated to be due to impaired bone resorption. First, *in vitro* study found decreased osteoclast numbers induced from the PBMCs of this patient. Second, circulating levels of RANKL and the RANKL/OPG ratio were significantly reduced in patient, which may lead to lower osteoclast formation. Furthermore, osteopetrosis cases due to impaired bone resorption tend to have increased fracture risks, while sclerosteosis cases secondary to enhanced bone formation do not [27]. This patient showed bilateral femoral neck fractures, further confirming the impaired bone resorption as a result of reduced osteoclast formation may be the main cause of HBM.

The most perplexing thing about this patient is his bone turnover status. There are some contradictions in his clinical manifestations, bone metabolism index and the circulating levels of SOST, DKK1, RANKL and OPG. Bone biopsy remains the gold standard to assess the true bone metabolism status. However, bone biopsy was not performed due to the poor bone quality of this patient. It is well known that primary hyperparathyroidism causes increased bone turnover and reduced BMD, especially at the cortical bone [28]. On the contrary, idiopathic hypoparathyroidism (IHP) cases often have reduced bone turnover and increased BMD than the general population [29, 30]. Compared with IHP and nonsurgical hypoparathyroidism (Ns-HypoPT) patients, PHP subjects, especially PHP type 1B, tend to have lower BMD, indicating incomplete skeletal resistance to PTH may exist [31-33]. However, when compared with normal

controls, patients with PHP1a showed a significantly greater total body BMD [34]. Furthermore, striking osteosclerosis has been found in two brothers diagnosed with PHP1b [35]. *Gsa* in skeleton is biallelically expressed. Therefore, no matter the origin of mutation is, *GNAS* mutation may lead to decreased skeletal response to PTH [36, 37]. It is reasonable to infer that bone turnover and bone metabolism status in PHP are closer to hypoparathyroidism than to hyperparathyroidism. However, the levels of bone metabolism indicators were significantly high in this patient. In other two studies, the levels of bone turnover markers were also high in subjects with PHP [31, 33]. It is notable that the proband's bone indicators, including B-ALP, OCN and CTX, showed a tendency to decrease during the past 4 years, despite the progressive increase in BMD. His persistent hypophosphatemia may play a role in the elevated B-ALP levels.

Our *in vitro* study clearly showed reduced osteoclast formation ability in this patient, which is consistent with the reduced RANKL/OPG ratio. Based on our experience, *in vitro* osteoclast culture could reliably reflect the osteoclast formation ability of humans [38]. Although this patient had increased CTX levels, we believe he had inhibited bone resorption as a result of decreased osteoclast formation, which is also consistent with osteopetrosis. As for bone formation, this patient had increased levels of SOST and DKK1, both of which could inhibit Wnt-mediated bone formation [27]. Furthermore, bone formation is coupled to bone resorption in general. Therefore, it is reasonable to infer that both bone resorption and bone formation were inhibited in this patient. The main physiological function of PTH is to promote bone resorption [5]. The impaired skeletal response to PTH may result in more inhibition on bone resorption than on bone formation, leading to increased bone mass (Figure 5). Therefore, we believe this patient belongs to a type of HBM with low bone turnover, primarily resulting from impaired bone resorption. Our study also suggests that exogenous RANKL may alleviate the

progressive increase in bone mass in this patient.

In the classic form of PHP, the PTH resistance is confined to the renal proximal tubule, leading to hypocalcemia, hyperphosphatemia, and elevated levels of PTH levels [39]. In fact, PTH resistance can occur either in the renal tubular level or the skeleton [39]. Given that the proband showed elevated serum PTH concurrently with increased phosphate excretion, it appears that PTH resistance is not present in the proximal tubule. In addition, urinary calcium excretion was extremely low, consistent with elevated PTH and a lack of resistance in distal nephron. In renal proximal tubules, *Gsa* is expressed only from the maternal allele, which may also apply to XLas based on patient-specific clinical data. Therefore, in this proband, the renal tubular response to PTH may be normal. We speculated the paternally inherited mutation located in XLas impaired skeletal response to PTH, leading to reduced serum calcium and elevated PTH level. The persistently elevated PTH caused hypophosphatemia. As a compensation, his serum calcium levels were maintained at the lower limit of the normal range.

It is notable that the patient showed unclosed coronal suture and sagittal suture. Unclosed cranial suture has also been reported in patients carrying mutations in runt-related transcription factor 2 (*Runx2*), which is known to affect metopic suture fusion and plays a key role in osteoblast differentiation mediated by Wnt-signaling pathway [40]. *Runx2* mutations have been described in subjects with cleidocranial dysplasia (CCD) (MIM 119600), which is a rare hereditary skeletal disorder [40, 41]. WES has excluded *Runx2* mutation in this patient. However, our study found increased circulating levels of *SOST* and *DKK1* in this patient, both of which could inhibit Wnt-pathway mediated bone formation. *Runx2* is one of the major target genes of activated Wnt-pathway [42], and the inhibited Wnt-signaling pathway may lead to reduced *Runx2* expression. Therefore, it is reasonable to speculate that the unclosed cranial

suture may be secondary to the impaired Wnt signaling and the resultant inhibited Runx2 expression (Figure 5).

His father also carried this mutation and the origin of mutant allele was unknown. It seemed that his father manifested a similar but milder phenotype. His daughter also carried the same mutation and presently showed no similar symptoms, possibly due to her young age or incomplete penetrance. It is suggested that XLas may be essential for normal fetal growth and development, and paternal mutations in XLas may lead to severe intrauterine growth retardation [11]. The birth records of this patient and his father were unknown. The daughter was born at term with a birth weight of about 2.6 kg and was well after birth. This family will be regularly followed up.

In conclusion, we first report a novel mutation located in the first exon of XLas in a patient with HBM, unclosed cranial suture, hypophosphatemia, and elevated PTH, indicating there is still a lot of ignorance about the physiopathologic roles of alternative GNAS gene products. The identification of cases with novel genetic and epigenetic defects indicates the urgent need for a new classification of this spectrum of diseases [5]. Our findings further expand the spectrum of clinical manifestation of diseases due to GNAS mutations, and also urge further investigation to explore the regulatory role of XLas in bone metabolism. Our study indicates that GNAS locus should be considered as a candidate gene for HBM.

Acknowledgments

This work was supported by grants from the National Natural Science Foundation of China (No. 81770875, 81572639, 81370969 to Xijie Yu) and the Science & Technology Department of Sichuan Province (2018SZ0142 to Xijie Yu). This study was also

supported by the National Natural Science Foundation of China (grant no. 81702156 to Y Meng), Postdoctoral Science Foundation of China (grant no. 2017M61060 to Y Meng) and Postdoctoral Research Foundation of Sichuan University (grant no. 2017SCU12038 to Y Meng). The authors thank Miss Xiao Yu from the University of Michigan, for her help with editing the language.

Authors' roles: Study design: Xiang Chen and Xijie Yu. Study conduct: Xiang Chen, Ying Xie, Shan Wan, Li Li, Jie Zhang and Bo Su. Data collection: Xiang Chen and Yang Meng. Data analysis: Xiang Chen. Data interpretation: Xiang Chen and Xijie Yu. Drafting manuscript: Xiang Chen. Revising manuscript content: Xijie Yu. Approving final version of manuscript: Xiang Chen and Xijie Yu. Xiang Chen and Xijie Yu take responsibility for the integrity of the data analysis.

REFERENCES

1. Nakamura A, Hamaguchi E, Horikawa R, Nishimura Y, Matsubara K, Sano S, et al. Complex Genomic Rearrangement Within the GNAS Region Associated With Familial Pseudohypoparathyroidism Type 1b. *J Clin Endocrinol Metab*. 2016;101(7):2623-2627. Epub 2016/06/03. doi: 10.1210/jc.2016-1725. PubMed PMID: 27253667.
2. de Nanclares GP, Fernandez-Rebollo E, Santin I, Garcia-Cuartero B, Gaztambide S, Menendez E, et al. Epigenetic defects of GNAS in patients with pseudohypoparathyroidism and mild features of Albright's hereditary osteodystrophy. *J Clin Endocrinol Metab*. 2007;92(6):2370-2373. Epub 2007/04/05. doi: 10.1210/jc.2006-2287. PubMed PMID: 17405843.
3. Lecumberri B, Fernandez-Rebollo E, Sentchordi L, Saavedra P, Bernal-Chico A, Pallardo LF, et al. Coexistence of two different pseudohypoparathyroidism subtypes (1a and 1b) in the same kindred with independent Gs{alpha} coding mutations and GNAS imprinting defects. *J Med Genet*. 2010;47(4):276-280. Epub 2009/10/28. doi: 10.1136/jmg.2009.071001. PubMed PMID: 19858129; PubMed Central PMCID: PMC3030964.
4. Turan S, Bastepe M. GNAS Spectrum of Disorders. *Curr Osteoporos Rep*. 2015;13(3):146-158. doi: 10.1007/s11914-015-0268-x. PubMed PMID: 25851935; PubMed Central PMCID: PMC4417430.
5. Mantovani G, Spada A, Elli FM. Pseudohypoparathyroidism and Gsalpha-cAMP-linked disorders: current view and open issues. *Nat Rev Endocrinol*. 2016;12(6):347-356. doi: 10.1038/nrendo.2016.52. PubMed PMID: 27109785.
6. Liu Z, Turan S, Wehbi VL, Vilardaga JP, Bastepe M. Extra-long Galphas variant XLalphas protein escapes activation-induced subcellular redistribution and is able to provide sustained signaling. *J Biol Chem*. 2011;286(44):38558-38569. Epub 2011/09/06. doi: 10.1074/jbc.M111.240150. PubMed PMID: 21890629; PubMed Central PMCID: PMC3207409.
7. Aydin C, Aytan N, Mahon MJ, Tawfeek HA, Kowall NW, Dedeoglu A, et al. Extralarge XL(alpha)s (XXL(alpha)s), a variant of stimulatory G protein alpha-subunit (Gs(alpha)), is a distinct, membrane-anchored GNAS product that can mimic Gs(alpha). *Endocrinology*. 2009;150(8):3567-3575. doi: 10.1210/en.2009-0318. PubMed PMID: 19423757; PubMed Central PMCID: PMC2717877.
8. Chen M, Gavrilova O, Liu J, Xie T, Deng C, Nguyen AT, et al. Alternative Gnas gene products have opposite effects on glucose and lipid metabolism. *Proc Natl Acad Sci U S A*. 2005;102(20):7386-7391. Epub 2005/05/11. doi: 10.1073/pnas.0408268102. PubMed PMID: 15883378; PubMed Central PMCID: PMC1129092.
9. Eaton SA, Williamson CM, Ball ST, Beechey CV, Moir L, Edwards J, et al. New mutations at the imprinted Gnas cluster show gene dosage effects of Gsalpha in postnatal growth and implicate XLalphas in bone and fat metabolism but not in suckling. *Mol Cell Biol*.

2012;32(5):1017-1029. Epub 2012/01/05. doi: 10.1128/MCB.06174-11. PubMed PMID: 22215617; PubMed Central PMCID: PMC3295192.

10. Giovanna M, Francesca Marta E. Multiple hormone resistance and alterations of G-protein-coupled receptors signaling. *Best Pract Res Clin Endocrinol Metab.* 2018;32(2):141-154. doi: 10.1016/j.beem.2018.01.002. PubMed PMID: 29678282.

11. Richard N, Molin A, Coudray N, Rault-Guillaume P, Juppner H, Kottler ML. Paternal GNAS mutations lead to severe intrauterine growth retardation (IUGR) and provide evidence for a role of XLalphas in fetal development. *J Clin Endocrinol Metab.* 2013;98(9):E1549-1556. Epub 2013/07/26. doi: 10.1210/jc.2013-1667. PubMed PMID: 23884777; PubMed Central PMCID: PMC3763972.

12. Plagge A, Gordon E, Dean W, Boiani R, Cinti S, Peters J, et al. The imprinted signaling protein XL alpha s is required for postnatal adaptation to feeding. *Nat Genet.* 2004;36(8):818-826. Epub 2004/07/27. doi: 10.1038/ng1397. PubMed PMID: 15273686.

13. Bastepe M, Gunes Y, Perez-Villamil B, Hunzelman J, Weinstein LS, Juppner H. Receptor-mediated adenylyl cyclase activation through XLalpha(s), the extra-large variant of the stimulatory G protein alpha-subunit. *Mol Endocrinol.* 2002;16(8):1912-1919. doi: 10.1210/me.2002-0054. PubMed PMID: 12145344.

14. Silva BC, Bilezikian JP. Parathyroid hormone: anabolic and catabolic actions on the skeleton. *Curr Opin Pharmacol.* 2015;22:41-50. Epub 2015/04/10. doi: 10.1016/j.coph.2015.03.005. PubMed PMID: 25854704; PubMed Central PMCID: PMC3763972.

15. Kondo H, Guo J, Bringham FR. Cyclic adenosine monophosphate/protein kinase A mediates parathyroid hormone/parathyroid hormone-related protein receptor regulation of osteoclastogenesis and expression of RANKL and osteoprotegerin mRNAs by marrow stromal cells. *J Bone Miner Res.* 2002;17(9):1667-1679. Epub 2002/09/05. doi: 10.1359/jbmr.2002.17.9.1667. PubMed PMID: 12211438.

16. Fu Q, Manolagas SC, O'Brien CA. Parathyroid hormone controls receptor activator of NF-kappaB ligand gene expression via a distant transcriptional enhancer. *Mol Cell Biol.* 2006;26(17):6453-6468. Epub 2006/08/18. doi: 10.1128/MCB.00356-06. PubMed PMID: 16914731; PubMed Central PMCID: PMC1592840.

17. Ben-awadh AN, Delgado-Calle J, Tu X, Kuhlenschmidt K, Allen MR, Plotkin LI, et al. Parathyroid hormone receptor signaling induces bone resorption in the adult skeleton by directly regulating the RANKL gene in osteocytes. *Endocrinology.* 2014;155(8):2797-2809. Epub 2014/06/01. doi: 10.1210/en.2014-1046. PubMed PMID: 24877630; PubMed Central PMCID: PMC3763972.

18. Kramer I, Keller H, Leupin O, Kneissel M. Does osteocytic SOST suppression mediate PTH bone anabolism? *Trends Endocrinol Metab.* 2010;21(4):237-244. Epub 2010/01/16. doi: 10.1016/j.tem.2009.12.002. PubMed PMID: 20074973.

19. Keller H, Kneissel M. SOST is a target gene for PTH in bone. *Bone.* 2005;37(2):148-158.

446 Epub 2005/06/11. doi: 10.1016/j.bone.2005.03.018. PubMed PMID: 15946907.

447 20. Silva BC, Costa AG, Cusano NE, Kousteni S, Bilezikian JP. Catabolic and anabolic
448 actions of parathyroid hormone on the skeleton. *J Endocrinol Invest.* 2011;34(10):801-810.
449 Epub 2011/09/29. doi: 10.3275/7925. PubMed PMID: 21946081; PubMed Central PMCID:
450 PMCPMC4315330.

451 21. Li JY, Walker LD, Tyagi AM, Adams J, Weitzmann MN, Pacifici R. The sclerostin-
452 independent bone anabolic activity of intermittent PTH treatment is mediated by T-cell-
453 produced Wnt10b. *J Bone Miner Res.* 2014;29(1):43-54. Epub 2013/12/21. doi:
454 10.1002/jbmr.2044. PubMed PMID: 24357520; PubMed Central PMCID: PMCPMC4326235.

455 22. Ardawi MS, Al-Sibiany AM, Bakhsh TM, Rouzi AA, Qari MH. Decreased serum sclerostin
456 levels in patients with primary hyperparathyroidism: a cross-sectional and a longitudinal study.
457 *Osteoporos Int.* 2012;23(6):1789-1797. doi: 10.1007/s00198-011-1806-8. PubMed PMID:
458 22041864.

459 23. Costa AG, Cremers S, Rubin MR, McMahon DJ, Sliney J, Jr., Lazaretti-Castro M, et al.
460 Circulating sclerostin in disorders of parathyroid gland function. *J Clin Endocrinol Metab.*
461 2011;96(12):3804-3810. doi: 10.1210/jc.2011-0566. PubMed PMID: 21937621; PubMed
462 Central PMCID: PMCPMC3232608.

463 24. Viapiana O, Fracassi E, Troplini S, Idolazzi L, Rossini M, Adami S, et al. Sclerostin and
464 DKK1 in primary hyperparathyroidism. *Calcif Tissue Int.* 2013;92(4):324-329. doi:
465 10.1007/s00223-012-9665-7. PubMed PMID: 23430197.

466 25. Nakchbandi IA, Lang R, Kinder B, Insogna KL. The role of the receptor activator of
467 nuclear factor-kappaB ligand/osteoprotegerin cytokine system in primary
468 hyperparathyroidism. *J Clin Endocrinol Metab.* 2008;93(3):967-973. doi: 10.1210/jc.2007-
469 1645. PubMed PMID: 18073309; PubMed Central PMCID: PMCPMC2266956.

470 26. Szymczak J, Bohdanowicz-Pawlak A. Osteoprotegerin, RANKL, and bone turnover in
471 primary hyperparathyroidism: the effect of parathyroidectomy and treatment with alendronate.
472 *Horm Metab Res.* 2013;45(10):759-764. doi: 10.1055/s-0033-1349842. PubMed PMID:
473 23888411.

474 27. Chen X, Yu H, Yu X. A Review of the Clinical, Radiological and Biochemical
475 Characteristics and Genetic Causes of High Bone Mass Disorders. *Curr Drug Targets.*
476 2018;19(6):621-635. Epub 2018/01/24. doi: 10.2174/1389450119666180122161503. PubMed
477 PMID: 29359663.

478 28. Eller-Vainicher C, Filopanti M, Palmieri S, Ulivieri FM, Morelli V, Zhukouskaya VV, et al.
479 Bone quality, as measured by trabecular bone score, in patients with primary
480 hyperparathyroidism. *Eur J Endocrinol.* 2013;169(2):155-162. doi: 10.1530/EJE-13-0305.
481 PubMed PMID: 23682095.

482 29. Chawla H, Saha S, Kandasamy D, Sharma R, Sreenivas V, Goswami R. Vertebral
483 Fractures and Bone Mineral Density in Patients With Idiopathic Hypoparathyroidism on Long-
484 Term Follow-Up. *J Clin Endocrinol Metab.* 2017;102(1):251-258. Epub 2016/11/05. doi:

485 10.1210/jc.2016-3292. PubMed PMID: 27813708.

486 30. Silva BC, Rubin MR, Cusano NE, Bilezikian JP. Bone imaging in hypoparathyroidism.

487 Osteoporos Int. 2017;28(2):463-471. doi: 10.1007/s00198-016-3750-0. PubMed PMID:

488 27577725.

489 31. Underbjerg L, Malmstroem S, Sikjaer T, Rejnmark L. Bone Status Among Patients With

490 Nonsurgical Hypoparathyroidism, Autosomal Dominant Hypocalcaemia, and

491 Pseudohypoparathyroidism: A Cohort Study. J Bone Miner Res. 2018;33(3):467-477. Epub

492 2017/11/01. doi: 10.1002/jbmr.3328. PubMed PMID: 29087612.

493 32. Chu X, Zhu Y, Wang O, Nie M, Quan T, Xue Y, et al. Bone Mineral Density and Its Serial

494 Changes Are Associated With PTH Levels in Pseudohypoparathyroidism Type 1B Patients. J

495 Bone Miner Res. 2018;33(4):743-752. doi: 10.1002/jbmr.3360. PubMed PMID: 29240265.

496 33. Kanatani M, Sugimoto T, Kaji H, Ikeda K, Chihara K. Skeletal responsiveness to

497 parathyroid hormone in pseudohypoparathyroidism. Eur J Endocrinol. 2001;144(3):263-269.

498 Epub 2001/03/15. PubMed PMID: 11248746.

499 34. Long DN, Levine MA, Germain-Lee EL. Bone mineral density in

500 pseudohypoparathyroidism type 1a. J Clin Endocrinol Metab. 2010;95(9):4465-4475. doi:

501 10.1210/jc.2010-0498. PubMed PMID: 20610593; PubMed Central PMCID:

502 PMC2936057.

503 35. Sbrocchi AM, Rauch F, Lawson ML, Hadjiyannakis S, Lawrence S, Bastepe M, et al.

504 Osteosclerosis in two brothers with autosomal dominant pseudohypoparathyroidism type 1b:

505 bone histomorphometric analysis. Eur J Endocrinol. 2011;164(2):295-301. doi: 10.1530/EJE-

506 10-0795. PubMed PMID: 21062889; PubMed Central PMCID: PMC3810006.

507 36. Nusynowitz ML, Frame B, Kolb FO. The spectrum of the hypoparathyroid states: A

508 classification based on physiologic principles. Medicine (Baltimore). 1976;55(2):105-119.

509 PubMed PMID: 768709.

510 37. Levine MA. An update on the clinical and molecular characteristics of

511 pseudohypoparathyroidism. Curr Opin Endocrinol Diabetes Obes. 2012;19(6):443-451. doi:

512 10.1097/MED.0b013e32835a255c. PubMed PMID: 23076042; PubMed Central PMCID:

513 PMC3679535.

514 38. Chen X, Zhang K, Hock J, Wang C, Yu X. Enhanced but hypofunctional

515 osteoclastogenesis in an autosomal dominant osteopetrosis type II case carrying a

516 c.1856C>T mutation in CLCN7. Bone Res. 2016;4:16035. Epub 2016/12/19. doi:

517 10.1038/boneres.2016.35. PubMed PMID: 27990310; PubMed Central PMCID:

518 PMC5126728.

519 39. Burnstein ML, Kottamasu SR, Pettifor JM, Sochett E, Ellis BI, Frame B. Metabolic bone

520 disease in pseudohypoparathyroidism: radiologic features. Radiology. 1985;155(2):351-356.

521 Epub 1985/05/01. doi: 10.1148/radiology.155.2.3983385. PubMed PMID: 3983385.

522 40. Jaruga A, Hordyjewska E, Kandzierski G, Tylzanowski P. Cleidocranial dysplasia and

523 RUNX2-clinical phenotype-genotype correlation. Clin Genet. 2016;90(5):393-402. doi:

524 10.1111/cge.12812. PubMed PMID: 27272193.
525 41. Karaguzel G, Akturk FA, Okur E, Gumele HR, Gedik Y, Okten A. Cleidocranial dysplasia:
526 a case report. J Clin Res Pediatr Endocrinol. 2010;2(3):134-136. doi: 10.4274/jcrpe.v2i3.134.
527 PubMed PMID: 21274329; PubMed Central PMCID: PMC3005677.
528 42. D'Alimonte I, Lannutti A, Pipino C, Di Tomo P, Pierdomenico L, Cianci E, et al. Wnt
529 signaling behaves as a "master regulator" in the osteogenic and adipogenic commitment of
530 human amniotic fluid mesenchymal stem cells. Stem Cell Rev. 2013;9(5):642-654. doi:
531 10.1007/s12015-013-9436-5. PubMed PMID: 23605563; PubMed Central PMCID:
532 PMCPMC3785124.
533

534

Figure legends

Figure 1. Radiographic features of this patient. (A). X-ray of skull showed unclosed coronal suture and sagittal suture (arrow). (B). Vertebral body showed diffuse increase in bone density. (C). Bilateral femoral neck fractures (arrow) and uneven density of pelvis. (D). Increased bone mineral density in femoral cortex.

Figure 2. Genetic analysis of GNAS mutation. (A). A missense mutation c.424G>T (p. G142X) in XLas was found in proband, his father and daughter. (B). This mutation exclusively affects XLas, but not Gsα.

Figure 3. *In vitro* osteoclast culture and expression of mutant or WT XLas in SaOS2 Cells. (A-B). TRAP staining of osteoclasts. (C-D). Adherent cells on the bone slices. (E-F) Pit formation after ultrasonic removal of the adherent cells. (G). The number of osteoclasts in the patient culture was significantly lower than that in the control culture. **p<0.01, compared with control. (H). The mRNA expression of WT and mutant XLas was significantly increased in the transfected SaOS2 cells. **p<0.01, compared with vector; ## p<0.01, compared with WT. (I). The production of cAMP induced by PTH in SaOS2 cells transfected with WT XLas was significantly higher than that in the empty vector group, which was blunted in G142X mutation. **p<0.01, compared with vector; ## p<0.01, compared with WT.

Figure 4. (A-C). SaOS2 cells transfected with empty vector. (D-F). SaOS2 cells transfected with WT XLas. EGFP-tagged WT XLas was localized to the plasma membrane and cytoplasm. (G-I). SaOS2 cells transfected with mutant XLas.

Figure 5. XLas mutation leads to selective skeletal resistance but normal renal tubular response to PTH.

559 Fig 1. Tif

560

561 Fig 2. tif
562

563 Fig 3. tif
564
565